ABclonal Biotechnology rakes in $92.9m Series C

ABclonal Biotechnology, a life science tools and services provider, has raised $92.9 million in Series C financing.

23 February 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles